LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023)

LENZ Therapeutics (LENZ) has 4 years of Preferred Stock Liabilities data on file, last reported at $143.4 million in Q4 2023.

• Preferred Stock Liabilities for Q4 2023 came in at $143.4 million, up 1349.41% year-over-year; the trailing twelve-month figure through Dec 2023 was $143.4 million (up 1349.41% YoY), and the FY2023 annual result was $143.4 million, up 1349.41% from the prior year.
• Preferred Stock Liabilities improved to $143.4 million in Q4 2023 per LENZ's latest filing, from $44.6 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $150.5 million in Q1 2021 and troughed at $5.9 million in Q2 2023.
• A 4-year average of $49.2 million and a median of $11.5 million in 2020 frame the typical range for Preferred Stock Liabilities.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 1349.41% in 2023 and fell as far as 1349.41% in 2023.
• A 4-year view of Preferred Stock Liabilities shows it stood at $55.6 million in 2020, then surged by 170.69% to $150.5 million in 2021, then slumped by 93.43% to $9.9 million in 2022, then jumped by 1349.41% to $143.4 million in 2023.
• Business Quant data shows LENZ's Preferred Stock Liabilities at $143.4 million in Q4 2023, $44.6 million in Q3 2023, and $5.9 million in Q2 2023.